Lyra Health Stock Price, Valuation & IPO
Last updated on 19 January 2022Lyra Health is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.
Source: AXEVIL investment team
Track Lyra Health Stock Price
We monitor the Lyra Health stock price based on the latest private market data and funding rounds. Since there is no Lyra Health stock symbol on public exchanges yet, we provide a consensus price to help you track your investment.
Lyra Health
Lyra Health is an American company providing psychological support through employers, founded in 2015 in Burlingame. Through corporate programs, the service is available to more than 20 million people worldwide; employees of Starbucks, Salesforce, and Morgan Stanley use it. Starbucks rejected a tender for a classic assistance program and launched Lyra at the start of the pandemic for 470 thousand employees — 99% of baristas immediately receive a matched specialist. Plumbing manufacturer Kohler in 2025 made Lyra its main partner instead of a set of disparate services: the first appointment is available within a day, 93% of participants are satisfied with the help. For defense contractor Peraton, in the first year, requests increased tenfold compared to the previous program. Series G led by Dragoneer took place at a valuation of $5.58 billion, with a total of approximately $890 million raised.
Key Metrics Dynamic
See the performance of Lyra Health's key metrics, based on real market data.
Funding rounds
Key highlights
Where Lyra Health stands today across technology, financials and market traction.
Starbucks: client since April 2020.
The company withdrew from the tender for the old assistance program and launched Lyra at the beginning of the pandemic for 470 thousand employees. 99% of baristas immediately receive a matched specialist.
Kohler: 28 thousand employees.
A plumbing fixture manufacturer in 2025 made Lyra the main partner instead of a set of disparate services. The first meeting is available the next day, 93% of participants are satisfied with the help.
Peraton: 10-fold increase in inquiries.
A defense contractor with 18 thousand people connected Lyra in 2024. In the first year, the number of requests increased tenfold compared to the previous program, and 86% of participants report improvement by the end of the assistance.
Frequently Asked Questions
Not on a public exchange — Lyra Health is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.
A private company has no single official share price. AXEVIL's consensus estimate is $18.23 per share as of 19 January 2022. Its most recent round implied a post-money valuation of $5.6B (January 2022).
Lyra Health's most recent funding round valued the company at $5.6B post-money (January 2022) — the latest primary-market measure of what the company is worth. Secondary trades can price its shares above or below that round.
No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.
No. Lyra Health is a private company and its shares are not listed on any public exchange.
No. Lyra Health has no ticker symbol because its shares are not listed on any exchange; a symbol is assigned only at an IPO or direct listing.
Get Updates
Stay informed about Lyra Health stock news and new investment rounds.
Risk disclosure and data sources
Secondary-market prices and investment round data on this page, current and historical, are based on publicly available information and on data from market participants, and are provided for informational purposes only. Axevil Capital strives for accuracy; all prices and valuations are approximate and may fluctuate significantly due to low liquidity and limited access to information. The secondary market for private company shares is illiquid and does not guarantee the ability to buy or sell shares at the displayed price.
Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.
Axevil Capital, LLC is a Delaware limited liability company (registration No. 6832739) operating as an investment adviser relying on an exemption from registration, filed with the SEC as an Exempt Reporting Adviser (SEC file No. 802-126907; CRD No. 323970). ERA status means the Company files reports with the SEC but is not a registered investment adviser. The Company is not a broker-dealer and is not a member of FINRA or SIPC.